Diabetes drug company call for approval

Wed, 24 Sep 2008
Diabetes drug company Takeda Pharmaceutical Co this week announced that it had applied for approval to market a joint diabetes treatment in the United States. The drug, which combines SYR-332 and blockbuster drug Actos, is available as a single tablet.

Actos, which will lose patent protection in America in 2011, has been a bestseller for Takeda. A spokeswoman for the company, Ayako Iwamuro, reportedly commented: "It is the world's first drug combining alogliptin (the generic name of SYR-322) and pioglitazone (the generic name of Actos). We see this providing us with a major foothold in coping with the impact of the patent expiry for Actos."

The earliest that the pharmaceutical company will get a decision on their drug will be in 10 months time.
Leave a Comment
Login via Facebook, Yahoo! and Hotmail
Have your full say in the Diabetes Forum
Your comments may be moderated. Please report any spam, illegal, offensive or libellous posts.